Evidence map›Paper›PMID 37555809›Full record

ArticleBioinformatics (Oxford, England)2023

Cancer drug response prediction with surrogate modeling-based graph neural architecture search.

Babatounde Moctard Oloulade, Jianliang Gao, Jiamin Chen, Raeed Al-Sabri, Zhenpeng Wu

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Babatounde Moctard OlouladeSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.ORCID 0000-0003-0078-2148
Jianliang GaoSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Jiamin ChenSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Raeed Al-SabriSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Zhenpeng WuSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationUnderstanding drug-response differences in cancer treatments is one of the most challenging aspects of personalized medicine. Recently, graph neural networks (GNNs) have become state-of-the-art methods in many graph representation learning scenarios in bioinformatics. However, building an optimal handcrafted GNN model for a particular drug sensitivity dataset requires manual design and fine-tuning of the hyperparameters for the GNN model, which is time-consuming and requires expert knowledge.

resultsIn this work, we propose AutoCDRP, a novel framework for automated cancer drug-response predictor using GNNs. Our approach leverages surrogate modeling to efficiently search for the most effective GNN architecture. AutoCDRP uses a surrogate model to predict the performance of GNN architectures sampled from a search space, allowing it to select the optimal architecture based on evaluation performance. Hence, AutoCDRP can efficiently identify the optimal GNN architecture by exploring the performance of all GNN architectures in the search space. Through comprehensive experiments on two benchmark datasets, we demonstrate that the GNN architecture generated by AutoCDRP surpasses state-of-the-art designs. Notably, the optimal GNN architecture identified by AutoCDRP consistently outperforms the best baseline architecture from the first epoch, providing further evidence of its effectiveness. AVAILABILITY AND IMPLEMENTATION: https://github.com/BeObm/AutoCDRP.

Indexed as

Antineoplastic AgentsNeoplasmsBenchmarkingComputational BiologyHumansNeural Networks, ComputerAntineoplastic Agents

Identifiers

PMID37555809
PMCPMC10432359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.